Cimetidine in colorectal cancer: immunological or adhesion-mediated effects?
Author Information
Author(s): Eaton D, Hawkins R E
Primary Institution: CRC Department of Medical Oncology, Christie Hospital NHS Trust
Conclusion
Cimetidine appears to have beneficial effects on colorectal cancer, potentially through immunological mechanisms and effects on E-selectin mediated adhesion.
Supporting Evidence
- Cimetidine improved 10-year survival rates in colorectal cancer patients with node-positive tumors.
- Previous studies have shown mixed results regarding cimetidine's effectiveness in various cancers.
- Immunomodulatory effects of cimetidine may enhance immune responses in colorectal cancer patients.
Takeaway
Cimetidine might help people with colorectal cancer by boosting their immune system and affecting how cancer cells stick to blood vessels.
Methodology
The publication discusses findings from various studies on cimetidine's effects in colorectal cancer, including a randomized placebo-controlled trial.
Potential Biases
The small size of some studies and exclusion of patients from analysis may introduce bias.
Limitations
The studies referenced have small sample sizes and some were not analyzed on an intention to treat basis.
Participant Demographics
Colorectal cancer patients, including those with node-positive tumors.
Statistical Information
P-Value
0.17
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website